MENU

Can Zoetis (ZTS) Stock Reach $95?

a pet medication company

A.I.Advisor
published price charts
A.I.Advisor
Nov 04, 2026

Can Zoetis (ZTS) Stock Reach $95?

Zoetis Inc. (ZTS), the world's largest animal-health company, has been one of the market's more volatile large-cap health-care names over the past year. After a sharp pullback from its 52-week high, investors are asking whether the stock can climb back toward a $95 stock price target. The answer depends less on a single catalyst than on whether the company can stabilize its core U.S. companion-animal franchise.

Key Takeaways

  • The central target discussed here is $95, the arithmetic mean of the eight verified analyst price targets that sit above Zoetis's latest price of $82.99.
  • Twelve current analyst targets were reviewed, ranging from $74 to $115; the overall mean of all twelve is about $90, which fell below the 10% threshold above the price, so the above-price average of $95 is used as the central target.
  • Reaching $95 would require a roughly 14% advance from the November 3, 2026 close of $82.99 — a substantial but not extreme move.
  • Supporting factors include a dominant animal-health franchise, a diversified companion-and-livestock mix, a low-teens P/E (price-to-earnings) ratio, and new products such as the osteoarthritis therapy Lenivia.
  • The biggest risks are softer U.S. companion-animal demand, generic competition in products like Convenia and Cerenia, safety scrutiny around Librela, and repeated guidance cuts.
  • The consensus rating is a Hold, but disagreement is wide — for example, J.P. Morgan holds a Buy with a $115 target while Goldman Sachs initiated at Hold with a $74 target.
  • For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for Zoetis.
  • You can also explore Trending AI Robots to see AI-driven strategies monitoring names like ZTS.

Analyst Price Targets and Consensus View

This analysis reviews twelve recent, individually attributable analyst price targets. Because the stock has been cut sharply, the targets cluster tightly below the old highs, producing a range of $74 to $115. The overall average of all twelve targets is roughly $90, only about 8% above the latest price. Since that falls short of a meaningful threshold, the central target here is the average of the eight targets that remain above the current price, which works out to about $95.

Sentiment is split. J.P. Morgan ($115, Buy, October 2026) and Citi ($96, Buy) remain constructive, while Goldman Sachs ($74, Hold, initiation) and Jefferies (downgraded to Hold, $83, October 2026) are more cautious. Morgan Stanley trimmed its target to $82 and UBS to $85. The common thread in the downgrades is concern that U.S. companion-animal demand is weakening faster than expected.

Current Market Position and Path Toward the Target

Zoetis closed at $82.99 on November 3, 2026, with a market value near $34 billion. Reaching $95 would require a gain of about 14%, which qualifies as a substantial move given the stock's 52-week range of $68.77 to $144.83. The path would likely depend on two things: stabilizing U.S. companion-animal sales, which management has said are being pressured by price sensitivity, fewer veterinary visits, and generics, and delivering on 2026 guidance that Wall Street has repeatedly marked down.

What Could Support a Move Toward the Target

Zoetis remains the clear industry leader, splitting revenue roughly 65% companion animal and 35% livestock. Its valuation is undemanding at a trailing P/E of roughly 13, with a dividend yield near 2.5% and a history of buybacks. New launches such as Lenivia, a long-acting osteoarthritis antibody approved in the UK, and strong international and livestock trends give bulls a reason to expect earnings to stabilize. If quarterly results on November 5 show companion-animal volumes bottoming, the depressed valuation could support a re-rating toward the $95 level.

What Could Prevent the Target From Being Reached

The risks are concrete. Zoetis has cut full-year guidance multiple times, and its second-quarter 2026 adjusted EPS guidance of roughly $6.15 to $6.25 sat well below the Street's prior consensus near $6.87. U.S. companion-animal sales have been declining, generic competition is eroding franchise products, and Librela-related safety concerns have triggered securities litigation. If demand weakness persists or competition intensifies, further target cuts — like Jefferies' move from $103 to $83 — could keep the stock pinned below $95.

Technical Levels and Market Structure

Technically, Zoetis has rebounded from its 52-week low near $68.77 toward the low $80s, putting the $80 round-number level into play as nearby support, with the $74–$75 area below it. On the upside, the $90 to $95 zone represents the first meaningful resistance cluster, followed by the psychological $100 level. The stock remains far below its prior $144.83 peak, so any sustained move toward $95 would likely require a durable shift in trend rather than a short-term bounce.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. The near-term catalyst is the November 5, 2026 earnings report, which will clarify companion-animal trends and any guidance update. Investors should also watch for further analyst revisions, commentary on Librela and Lenivia, generic competition in Convenia and Cerenia, and broader consumer-spending signals that affect veterinary demand.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like Zoetis, such tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. Traders looking to complement their research can explore these signals to stay ahead of emerging moves.

Final Assessment

Can Zoetis reach $95? The question is reasonable but not assured. The $95 central target reflects only the analyst targets that remain above today's price, while the broader range of $74 to $115 shows genuine disagreement about the company's trajectory. A 14% advance is achievable if companion-animal demand stabilizes and the low valuation re-rates, but persistent guidance cuts, generics, and Librela-related litigation are real obstacles. The November earnings report and subsequent analyst revisions will be the clearest test of whether the $95 level is a realistic milestone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

ZTS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with PAHC. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
-1.08%
PAHC - ZTS
58%
Loosely correlated
-0.29%
ELAN - ZTS
47%
Loosely correlated
-2.12%
PBH - ZTS
36%
Loosely correlated
+0.46%
SNDL - ZTS
33%
Loosely correlated
N/A
AMPH - ZTS
33%
Poorly correlated
-0.24%
More

Groups containing ZTS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
-1.08%
Pharmaceuticals: Generic
industry (81 stocks)
0%
Poorly correlated
-0.07%